Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-09

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF. The Morpheus8 Applicator and 24 pin tip is used for the treatment of primary hyperhidrosis of the axillae

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Image Guided Targeted Photoablation for the Treatment of Localized Hyperhidrosis

NCT04178161

Hyperhidrosis

UNKNOWN NA

Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis

NCT02100072

Hyperhidrosis

COMPLETED NA

Single-Treatment, Study of Percutaneous-Temperature Controlled-RF Electrocoagulation on Axilla Tissue

NCT03107065

Sweating Increased Armpits

COMPLETED NA

Bilateral Endoscopic Thoracic T3 Sympathectomy Versus T3 Radiofrequency Ablation for Primary Palmar Hyperhidrosis

NCT05737914

Primary Palmar Hyperhydrosis

UNKNOWN NA

Clinical Evaluation of the miraDry System in Subjects With Hyperhidrosis

NCT01091129

Axillary Hyperhidrosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study subjects will be consecutively screened and enrolled into the study. The study will consist of an active group that will receive 2 treatments with the InMode radio frequency Pro System with the Morpheus8 Applicator (with the 24 pin tip) and a sham group that will receive 2 sham treatments with the same InMode radio frequency Pro System and Morpheus8 Applicator (with a sham 24 pin tip). Treatment will be performed in a preheated controlled environment (T°≥22°C). Follow up visits will occur at 1 month, 3 months, and 6 months post treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperhidrosis Primary Focal Axilla

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Study subjects will be consecutively screened and enrolled into the study. The study will consist of an active group that will receive 2 treatments with the InMode RF Pro System with the Morpheus8 Applicator (with the 24 pin tip) and a sham group that will receive 2 sham treatments with the same InMode RF Pro System and Morpheus8 Applicator (with a sham 24 pin tip). Treatment will be performed in a preheated controlled environment (T°≥22°C). Follow up visits will occur at 1 month, 3 months, and 6 months post treatment.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

The treatments will be performed by an operator/technician who will not be blinded to the type of treatment that the subject is receiving. Objective assessment of clinical improvements such as starch-iodine tests will administered by blinded study personnel. The blinded evaluators will review photographs of the treatment areas that underwent the starch-iodine test and will be blinded as to which photos were taken at the baseline, 4-week follow-up, 12-week follow-up and 24-week follow-up visits. The HDSS, which is an objective assessment, will also be evaluated by a blinded study personnel. All subjects and study staff will be unblinded at the end of the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active group

Active group that will receive 2 treatments with the InMode RF Pro System with the Morpheus8 Applicator (with the 24 pin tip)

Group Type ACTIVE_COMPARATOR

Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.

Intervention Type DEVICE

After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment

Sham group

Sham group that will receive 2 sham treatments with the same InMode RF Pro System and Morpheus8 Applicator (with a sham 24 pin tip).

Group Type SHAM_COMPARATOR

Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.

Intervention Type DEVICE

After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.

After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subject is 18 years of age or older at the time of consent.

* Subject reports a quality-of-life rating of 3 or 4 on the Hyperhidrosis Disease Severity Scale (HDSS).
* Subject has primary focal axillary hyperhidrosis evidenced by at least 6 months of visible, detectable, focal, exaggerated sweating without any apparent explanation and at least two of the following:
* Bilateral and relatively symmetric
* Impairs daily activities
* Frequency of at least one episode per week
* Age of onset less than 25 years old
* Positive family history
* Cessation of focal sweating during sleep
* Subject is willing and able to comply with protocol requirements and all study visits
* Willing to have de-identified images of the treated areas taken for possible use in publications and presentations.
* Subject understands the study and has provided written informed consent

Exclusion Criteria

Subject has secondary hyperhidrosis due to medications, infections, malignancy or endocrinopathy.

* Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
* Severe concurrent conditions such as cardiac disorders epilepsy, uncontrolled hypertension, and liver or kidney diseases.
* Any active skin condition in the treatment area, such as sores, psoriasis, eczema and rash.
* Swollen axillary lymph nodes.
* History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
* Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.
* History of bleeding coagulopathies or use of anticoagulants in the last 10 days.
* Prior endoscopic thoracic sympathectomy, liposuction or other surgery for hyperhidrosis in the treated area. Injection of botulinum toxin in the treated area within one year
* Use of Isotretinoin (Accutane®) within 6 months prior to study
* Oral anticholinergic medication use (e.g., Robinul) or cholinomimetic medication use within the last 4 weeks or planned use during the study's follow up phase.
* Currently participating in or recently participated in another clinical trial (within the last 30 days).
* History of or current neurologic deficit in the treatment limb.
* Known resistance to or history of difficulty with local anesthesia (lidocaine with epinephrine).
* Current or history of cancer, including skin cancer, or premalignant moles.
* Injury in the treatment area or any other condition that, in the opinion of the investigator, might make treatment unsafe.
* Subject has a pacemaker, defibrillator or other electronic implant anywhere in the body.
* Permanent implant in the treated area such as metal plates, screws and metal piercing or silicon.
* Females who are pregnant or nursing
* Female subjects of childbearing potential not willing to use an acceptable form of contraception for the duration of the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes